Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians

Eric Van Cutsem, Henk M W Verheul, Patrik Flamen, Philippe Rougier, Regina Beets-Tan, Rob Glynne-Jones, Thomas Seufferlein

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

The use of imaging in colorectal cancer (CRC) has significantly evolved over the last twenty years, establishing important roles in surveillance, diagnosis, staging, treatment selection and follow up. The range of modalities has broadened with the development of novel tracer and contrast agents, and the fusion of technologies such as positron emission tomography (PET) and computed tomography (CT). Traditionally, the most widely used modality for assessing treatment response in metastasised colon and rectal tumours is CT, combined with use of the RECIST guidelines. However, a growing body of evidence suggests that tumour size does not always adequately correlate with clinical outcomes. Magnetic resonance imaging (MRI) is a more versatile technique and dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI may be used to evaluate biological and functional effects of treatment. Integrated fluorodeoxyglucose (FDG)-PET/CT combines metabolic and anatomical imaging to improve sensitivity and specificity of tumour detection, and a number of studies have demonstrated improved diagnostic accuracy of this modality in a variety of tumour types, including CRC. These developments have enabled the progression of treatment strategies in rectal cancer and improved the detection of hepatic metastatic disease, yet are not without their limitations. These include technical, economical and logistical challenges, along with a lack of robust evidence for standardisation and formal guidance. In order to successfully apply these novel imaging techniques and utilise their benefit to provide truly personalised cancer care, advances need to be clinically realised in a routine and robust manner.

Original languageEnglish
JournalCancers
Volume8
Issue number9
DOIs
Publication statusPublished - 31 Aug 2016

Cite this

Van Cutsem, E., Verheul, H. M. W., Flamen, P., Rougier, P., Beets-Tan, R., Glynne-Jones, R., & Seufferlein, T. (2016). Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers, 8(9). https://doi.org/10.3390/cancers8090081
Van Cutsem, Eric ; Verheul, Henk M W ; Flamen, Patrik ; Rougier, Philippe ; Beets-Tan, Regina ; Glynne-Jones, Rob ; Seufferlein, Thomas. / Imaging in Colorectal Cancer : Progress and Challenges for the Clinicians. In: Cancers. 2016 ; Vol. 8, No. 9.
@article{98dbdc67dd2a48ac98262fd260d45e6d,
title = "Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians",
abstract = "The use of imaging in colorectal cancer (CRC) has significantly evolved over the last twenty years, establishing important roles in surveillance, diagnosis, staging, treatment selection and follow up. The range of modalities has broadened with the development of novel tracer and contrast agents, and the fusion of technologies such as positron emission tomography (PET) and computed tomography (CT). Traditionally, the most widely used modality for assessing treatment response in metastasised colon and rectal tumours is CT, combined with use of the RECIST guidelines. However, a growing body of evidence suggests that tumour size does not always adequately correlate with clinical outcomes. Magnetic resonance imaging (MRI) is a more versatile technique and dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI may be used to evaluate biological and functional effects of treatment. Integrated fluorodeoxyglucose (FDG)-PET/CT combines metabolic and anatomical imaging to improve sensitivity and specificity of tumour detection, and a number of studies have demonstrated improved diagnostic accuracy of this modality in a variety of tumour types, including CRC. These developments have enabled the progression of treatment strategies in rectal cancer and improved the detection of hepatic metastatic disease, yet are not without their limitations. These include technical, economical and logistical challenges, along with a lack of robust evidence for standardisation and formal guidance. In order to successfully apply these novel imaging techniques and utilise their benefit to provide truly personalised cancer care, advances need to be clinically realised in a routine and robust manner.",
keywords = "Journal Article, Review",
author = "{Van Cutsem}, Eric and Verheul, {Henk M W} and Patrik Flamen and Philippe Rougier and Regina Beets-Tan and Rob Glynne-Jones and Thomas Seufferlein",
year = "2016",
month = "8",
day = "31",
doi = "10.3390/cancers8090081",
language = "English",
volume = "8",
journal = "Cancers (Basel)",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "9",

}

Van Cutsem, E, Verheul, HMW, Flamen, P, Rougier, P, Beets-Tan, R, Glynne-Jones, R & Seufferlein, T 2016, 'Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians' Cancers, vol. 8, no. 9. https://doi.org/10.3390/cancers8090081

Imaging in Colorectal Cancer : Progress and Challenges for the Clinicians. / Van Cutsem, Eric; Verheul, Henk M W; Flamen, Patrik; Rougier, Philippe; Beets-Tan, Regina; Glynne-Jones, Rob; Seufferlein, Thomas.

In: Cancers, Vol. 8, No. 9, 31.08.2016.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Imaging in Colorectal Cancer

T2 - Progress and Challenges for the Clinicians

AU - Van Cutsem, Eric

AU - Verheul, Henk M W

AU - Flamen, Patrik

AU - Rougier, Philippe

AU - Beets-Tan, Regina

AU - Glynne-Jones, Rob

AU - Seufferlein, Thomas

PY - 2016/8/31

Y1 - 2016/8/31

N2 - The use of imaging in colorectal cancer (CRC) has significantly evolved over the last twenty years, establishing important roles in surveillance, diagnosis, staging, treatment selection and follow up. The range of modalities has broadened with the development of novel tracer and contrast agents, and the fusion of technologies such as positron emission tomography (PET) and computed tomography (CT). Traditionally, the most widely used modality for assessing treatment response in metastasised colon and rectal tumours is CT, combined with use of the RECIST guidelines. However, a growing body of evidence suggests that tumour size does not always adequately correlate with clinical outcomes. Magnetic resonance imaging (MRI) is a more versatile technique and dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI may be used to evaluate biological and functional effects of treatment. Integrated fluorodeoxyglucose (FDG)-PET/CT combines metabolic and anatomical imaging to improve sensitivity and specificity of tumour detection, and a number of studies have demonstrated improved diagnostic accuracy of this modality in a variety of tumour types, including CRC. These developments have enabled the progression of treatment strategies in rectal cancer and improved the detection of hepatic metastatic disease, yet are not without their limitations. These include technical, economical and logistical challenges, along with a lack of robust evidence for standardisation and formal guidance. In order to successfully apply these novel imaging techniques and utilise their benefit to provide truly personalised cancer care, advances need to be clinically realised in a routine and robust manner.

AB - The use of imaging in colorectal cancer (CRC) has significantly evolved over the last twenty years, establishing important roles in surveillance, diagnosis, staging, treatment selection and follow up. The range of modalities has broadened with the development of novel tracer and contrast agents, and the fusion of technologies such as positron emission tomography (PET) and computed tomography (CT). Traditionally, the most widely used modality for assessing treatment response in metastasised colon and rectal tumours is CT, combined with use of the RECIST guidelines. However, a growing body of evidence suggests that tumour size does not always adequately correlate with clinical outcomes. Magnetic resonance imaging (MRI) is a more versatile technique and dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI may be used to evaluate biological and functional effects of treatment. Integrated fluorodeoxyglucose (FDG)-PET/CT combines metabolic and anatomical imaging to improve sensitivity and specificity of tumour detection, and a number of studies have demonstrated improved diagnostic accuracy of this modality in a variety of tumour types, including CRC. These developments have enabled the progression of treatment strategies in rectal cancer and improved the detection of hepatic metastatic disease, yet are not without their limitations. These include technical, economical and logistical challenges, along with a lack of robust evidence for standardisation and formal guidance. In order to successfully apply these novel imaging techniques and utilise their benefit to provide truly personalised cancer care, advances need to be clinically realised in a routine and robust manner.

KW - Journal Article

KW - Review

U2 - 10.3390/cancers8090081

DO - 10.3390/cancers8090081

M3 - Article

VL - 8

JO - Cancers (Basel)

JF - Cancers (Basel)

SN - 2072-6694

IS - 9

ER -

Van Cutsem E, Verheul HMW, Flamen P, Rougier P, Beets-Tan R, Glynne-Jones R et al. Imaging in Colorectal Cancer: Progress and Challenges for the Clinicians. Cancers. 2016 Aug 31;8(9). https://doi.org/10.3390/cancers8090081